| Income Statement | 2026-02-28 | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|---|
| Revenue | 20 | 0 | 169* | 174 |
| Cost of goods sold | 0 | 0 | -1* | 0 |
| Gross profit | 20 | 0 | 170* | 174 |
| Research and development | 475.388 | 671.34 | 1,268* | 2,717.501 |
| General and administrative | 996.515 | 902.291 | 1,157* | 1,206.92 |
| Total operating expenses | 1,471.903 | 1,573.631 | 2,425* | 3,924.421 |
| Loss from operations | -1,451.903 | -1,573.631 | -2,255* | -3,750.421 |
| Interest income | 1.769 | 0.012 | 3* | 0.19 |
| Unrealized loss (gain) on marketable securities | 0 | -22.093 | 87* | -40.375 |
| Total other income (gain) | 1.769 | -22.081 | 90* | -40.185 |
| Net loss before income taxes | -1,450.134 | -1,595.712 | NaN | NaN |
| Income taxes | 2.598 | 1.791 | NaN | NaN |
| Net loss | -1,452.732 | -1,597.503 | -2,165* | -3,790.606 |
| Less net loss attributable to non-controlling interest | -2.753 | -2.496 | -3* | -1.514 |
| Net loss attributable to lexaria shareholders | -1,449.979 | -1,595.007 | -2,162* | -3,789.092 |
| Foreign currency translation adjustment | 20.635 | -5.744 | -102* | 37.173 |
| Total comprehensive loss | -1,429.344 | -1,600.751 | -2,264 | -3,751.919 |
| Diluted EPS | -0.06 | -0.07 | -0.119 | -0.21 |
| Diluted Average Shares | 24,443,846 | 21,376,029 | 19,029,323 | 18,298,309 |
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)